Lilly sues two more Texas compounding pharmacies over tirzepatide replicas
Lilly's compounding lawsuits now reach 34 states, which could affect where patients can buy compounded tirzepatide products.
Eli Lilly sued two more Texas compounding pharmacies on October 27, 2025, alleging they sold replicas of its tirzepatide medicines Mounjaro and Zepbound [1]. The new filings widen a multistate legal campaign that Lilly has now taken to 34 states [1].
Both defendants are Texas compounding pharmacies, the latest companies to be sued in what the report describes as Lilly's battle to stop production of copies of its diabetes and weight loss drugs [1]. One complaint referenced is captioned Eli Lilly v. North American Custom Laboratories [1]. The second company is not named in the report, and no response from either company has been reported [1].
Lilly alleges the companies illegally mass-produced "knock-offs" of its GLP-1 drugs, Mounjaro and Zepbound [1]. Mounjaro and Zepbound are the company's tirzepatide medicines, which the report groups among drugs for diabetes and weight loss [1]. The report does not describe the products at issue beyond calling them replicas [1].
Novo Nordisk, which sells the GLP-1 drug Ozempic, has filed its own lawsuits against compounding sellers in almost 40 states [1]. Ozempic contains semaglutide, a different molecule from tirzepatide [1].
Several basics are not yet known. The report does not give the dollar amounts Lilly is seeking, name the court hearing the cases, or say whether the two pharmacies have hired lawyers [1]. It also does not say whether the products at issue were shipped outside Texas or how many patients bought them [1].
Why it matters for patients
The lawsuits are aimed at sellers, not at the FDA-approved brand products Mounjaro and Zepbound [1]. That means the filings themselves do not change what is available by prescription from a pharmacy, but they do put more pressure on the businesses that sell compounded versions of the same molecule.
If a court rules for Lilly, a compounding seller could be barred from making or selling its version of tirzepatide, though no ruling in these cases has been reported [1]. Patients who get tirzepatide from a compounding pharmacy may find that their seller is one of the companies now named in litigation, and that the product's availability or name changes as cases move forward. The report does not say whether any of the pharmacies have stopped selling the products since being sued [1].
The numbers also show how broad the legal fight has become. Lilly has filed in 34 states, and Novo Nordisk in almost 40 [1]. For patients, that means the rules around compounded GLP-1 products may vary depending on where they live and who sells to them.
What happens next
No hearing dates, rulings or settlements have been reported in the two new Texas cases [1]. Both companies' litigation campaigns are continuing to add defendants, with Lilly at 34 states and Novo Nordisk at almost 40 [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.